Skip to main content

Nivolumab plus ipilimumab boosts response rate in refractory esophagogastric cancer

Primary tabs

View
Get Stamp Tags
Published Locations

Breadcrumb

Home
Nivolumab plus ipilimumab boosts response rate in refractory esophagogastric cancer

User login

Username

Password

Reset your password

Type	Lead	score